TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
1.270
-0.110 (-7.97%)
Apr 1, 2025, 4:00 PM EDT - Market closed

TScan Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Net Income
-127.5-89.22-66.22-48.63-26.13
Upgrade
Depreciation & Amortization
4.115.365.143.331.23
Upgrade
Loss (Gain) From Sale of Assets
----0
Upgrade
Loss (Gain) From Sale of Investments
-3.9-1.07---
Upgrade
Stock-Based Compensation
9.555.214.552.520.52
Upgrade
Other Operating Activities
1.860.760.26--
Upgrade
Change in Accounts Payable
1.99-0.050.530.011.13
Upgrade
Change in Unearned Revenue
-2.8211.89-9.03-6.5419.44
Upgrade
Change in Other Net Operating Assets
5.885.77-1.730.630.79
Upgrade
Operating Cash Flow
-110.82-61.36-66.5-48.68-3.02
Upgrade
Capital Expenditures
-3.83-3.15-4.23-9.94-4.24
Upgrade
Investment in Securities
-48.79-57.61---
Upgrade
Investing Cash Flow
-52.61-60.76-4.23-9.94-4.24
Upgrade
Long-Term Debt Issued
32.46-29.35--
Upgrade
Long-Term Debt Repaid
-17.14----
Upgrade
Net Debt Issued (Repaid)
15.31-29.35--
Upgrade
Issuance of Common Stock
35.1843.130.3389.940.29
Upgrade
Other Financing Activities
158.2792.32-0.32--
Upgrade
Financing Cash Flow
208.77135.4429.36189.670.29
Upgrade
Net Cash Flow
45.3313.33-41.37131.05-6.97
Upgrade
Free Cash Flow
-114.65-64.5-70.73-58.62-7.26
Upgrade
Free Cash Flow Margin
-4071.27%-306.45%-522.56%-578.03%-669.22%
Upgrade
Free Cash Flow Per Share
-2.03-1.35-2.94-5.03-7.93
Upgrade
Cash Interest Paid
2.8830.66--
Upgrade
Levered Free Cash Flow
-68.97-41.83-42.84-33.43-5.85
Upgrade
Unlevered Free Cash Flow
-66.69-39.48-42.1-33.43-5.85
Upgrade
Change in Net Working Capital
-7.74-11.515.92-1.07-13.04
Upgrade
Updated Mar 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q